ScinoPharm Taiwan Ltd (台灣神隆), which makes made-to-order active pharmaceutical ingredients (API), yesterday completed the second stage of construction on its factory in Changshu in China’s Jiangsu Province.
The plant is set to boost the company’s total reactor volume by between 2.04 and 2.69 times to between 341,960 and 371,630 liters on both sides of the Taiwan Strait.
ScinoPharm’s pharmaceutical plant in Greater Tainan has a reactor volume of between 14,580 and 44,250 liters.
The second stage of construction included the building of a research and development center, as well as a multipurpose API plant, which can supply a larger variety of ingredients thanks to its two large production lines, the company said.
ScinoPharm has invested US$50 million to US$60 million in the two-stage project on a 40 hectare plot of land in the Chinese city, company president and chief executive Jo Shen (馬海怡) said yesterday.
The company plans to invest the same amount to build a formulation factory and expand its API production capacity on a nearby plot of land of a smiliar size, Shen said.
ScinoPharm has not made a timetable for its future investment because the schedule will depend on whether it can find Chinese partners to produce formulations, she said.
The Changshu factory has received drug production licenses from China’s Food and Drug Administration to manufacture four API products, but ScinoPharm still needs to apply for China’s good manufacturing practices certificates and drug permits for the four products before it can sell them on the market, she added.
ScinoPharm general manager Cheng Kuo-hsi (鄭國喜) said the factory is the first pharmaceutical plant in China that has complied with the country’s new good manufacturing standards.
The factory is expected to receive two drug permits in 2015 and 2016, after ScinoPharm and one of its clients submit the applications next year, Cheng said.
The Chinese facility began supplying intermediates to the company’s Greater Tainan factory in the second half of last year and is making drugs on a contract basis for two US companies and one Chinese firm, he added.
Meanwhile, the pharmaceutical ingredient maker is working with Chinese partners to sell its products across the Taiwan Strait and is in talks with another company in China to make drugs to treat glaucoma, according to Shen.
In Taiwan, ScinoPharm is building new production lines at its formulation factory in Greater Tainan, which may begin operating in the third quarter of next year, she said.
Alex Lo (羅智先), chairman of Uni-President Enterprise Co (統一企業), one of ScinoPharm’s largest shareholders, attended at the factory’s opening ceremony yesterday.
Companies affiliated with Uni-President own more than 60 percent of ScinoPharm shares.
Lo said Uni-President plans to follow in the footsteps of ScinoPharm and join its investment project.
“Uni-President will need the expertise of ScinoPharm to codevelop health products for the elderly,” he said.
From January through last month, ScinoPharm Taiwan registered revenue of NT$4.44 billion, up 9.87 percent from the NT$4.04 billion it made a year ago, while its net profit for the first three quarters was NT$1 billion, or NT$1.49 per share, up from NT$748.37 million, or NT$1.11 per share, the previous year.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
Merck Group Taiwan yesterday said that it plans to invest substantially on expanding its fab in Kaohsiung’s Lujhu District (路竹) to better serve its local customers, including Taiwan Semiconductor Manufacturing Co (TSMC, 台積電). The company said it plans to expand its production space by 50 percent in the next five years and its workforce by about 40 percent, Merck Group Taiwan managing director Dick Hsieh (謝志宏) told a media briefing in Taipei. Hsieh declined to disclose investment details, but said that the latest investment would exceed the total amount Merck has invested in Taiwan over the past few years. Those investments would be
INVEST IN TAIWAN: A metal components casting firm and the world’s largest maker of aluminum bicycle rims also obtained approvals to join the program Solar Applied Materials Technology Co (SOLAR, 光洋應用材料), a part of Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) “green supply chain,” has pledged to invest NT$1 billion (US$34.1 million) to build a new plant at the Tainan Technology Industrial Park (台南科技工業區), the Ministry of Economic Affairs said yesterday. SOLAR has been collaborating with TSMC to extract precious metals from waste and reuse them as “sputtering target” material in high-end semiconductor manufacturing, a TSMC press release issued in May said. Established in 1978, SOLAR also offers key materials and integrated services to customers in the optoelectronics, information and communications technology, petrochemicals and consumer electronics industries,
‘SWARM TECH’: Joint venture FARobot is to develop autonomous mobile robots that would first be deployed in Hon Hai’s factories to optimize production efficiency Hon Hai Precision Industry Co (鴻海精密) and Adlink Technology Inc (凌華科技) have formed a robotic venture that aims to use “swarm technology” to create robots that can communicate with one another on the factory floor to optimize production efficiency. Hon Hai is Apple Inc’s leading iPhone assembler and the world’s largest contract electronics maker, while Adlink supplies industrial computers and Internet of Things solutions. Through a subsidiary, Hyield Venture Capital Co (鴻揚創投), Hon Hai holds a 51 percent stake in autonomous mobile robot (AMR) developer FARobot (法博智能移動), while Adlink owns the remaining 49 percent. Together, the two companies put up NT$200